CADTH Canadian Drug Expert Committee recommendation. indication : chronic hepatitis C virus infection. Glecaprevir / Pibrentasvir (Maviret -- Abbvie Corporation) :
The CADTH Canadian Drug Expert Committee (CDEC) recommends that glecaprevir/pibrentasvir (GP) be reimbursed for the treatment of adult patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis, including patients with HCV genotype 1 infection who were previously...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK533338/ Full text |
|---|---|
| Corporate Author: | |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2018
|
| Edition: | Version 1.0. |
| Series: | Common drug review clinical review report.
|
| Subjects: |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that glecaprevir/pibrentasvir (GP) be reimbursed for the treatment of adult patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis, including patients with HCV genotype 1 infection who were previously treated with either a regimen of NS5A inhibitor or with a NS3/4A protease inhibitor but not with both classes of inhibitors. |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 online resource (1 PDF file (7 pages)). |
| Source of Description, Etc. Note: | Description based on online resource; title from PDF title page (viewed March 4, 2019). |
| Funding Information Note: | Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. |
